预约演示
更新于：2025-07-11
Azathioprine
硫唑嘌呤
更新于：2025-07-11
概要
基本信息
药物类型 小分子化药 |
别名 AZA-DR、Azathioprine (JP17/USP/INN)、BW-57-322 + [11] |
靶点 |
作用方式 抑制剂 |
作用机制 DNA抑制剂(DNA抑制剂) |
在研适应症 |
非在研适应症- |
原研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C9H7N7O2S |
InChIKeyLMEKQMALGUDUQG-UHFFFAOYSA-N |
CAS号446-86-6 |
关联
176
项与 硫唑嘌呤 相关的临床试验NCT06941376
Pragmatic, Open-Label, Two-Stage, Pilot Study of Effectiveness of Immunomodulatory Medications for Patients With Relapsing Polychondritis
NCT05545384
Immediate Versus Delayed Treatment With Azathioprine or Rituximab in Anti-myelin Oligodendrocytes Glycoprotein (Anti-MOG) Antibodies Associated Acute Demyelinating Syndromes in Children: a Randomized Controlled Clinical Trial
NCT07044141
Efficacy of Oral Tofacitinib in Combination With Narrow Band UVB in the Treatment of Vitiligo
100 项与 硫唑嘌呤 相关的临床结果
登录后查看更多信息
100 项与 硫唑嘌呤 相关的转化医学
登录后查看更多信息
100 项与 硫唑嘌呤 相关的专利（医药）
登录后查看更多信息
25,671
项与 硫唑嘌呤 相关的文献（医药）2025-12-31Future Science OA
Colonic strictures in Crohn’s disease: a non-surgical survival
Article
作者: Souissi, Salma ; Boubaker, Jalel ; Jaziri, Hanene ; Labidi, Asma ; Ben Mustapha, Nadia ; Laabidi, Sarra ; Haddad, Anis ; Sebai, Amine ; Aboubecrine, Hamed ; Serghini, Meriem ; Gouiaa, Donia ; Fekih, Monia
BACKGROUND:
Colonic stenosis in Crohn's disease (CD) is uncommon, and data on surgery-free survival are limited. This study aimed to determine surgery-free survival rates and identify associated factors.
PATIENTS AND METHODS:
A retrospective study was conducted from 2003 to 2022, including patients with CD complicated by colonic stenosis. Patients with uncertain diagnoses or follow-up periods of less than six months were excluded.
RESULTS:
Fifty-six patients were included (median age 44 years [range 14-65], male-to-female ratio = 0.93). Surgery-free survival rates were 58.9% at 6 months, 43.7% at 2 years, and 31.7% at 5 years, with an average surgery-free survival of 46.7 months. Univariate analysis showed that joint manifestations (p = 0.01), corticosteroids (p = 0.02), anti-TNF alpha (p = 0.02), salicylates (p = 0.02), and azathioprine (p = 0.01) increased surgery-free survival. Complications such as collections or internal fistulas (p = 0.03), parietal ulceration on imaging (p = 0.01), and acute intestinal obstruction (p = 0.01) were associated with reduced surgery-free survival. In multivariate analysis, biologic therapy was the only independent protective factor against surgery (p = 0.001, OR = 0.19).
CONCLUSION:
The early introduction of biologic therapy is crucial for increasing surgery-free survival in patients with colonic stenosis in CD, given the limited effectiveness of conventional treatments.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Diverse Clinical and Immunological Profiles in Patients with IPEX Syndrome: a Multicenter Analysis from Turkey
Article
作者: Bozkurt, Selcen ; Bilgic Eltan, Sevgi ; Yalcin Gungoren, Ezgi ; Bayram Catak, Feyza ; Kiykim, Ayca ; Can, Salim ; Amirov, Razin ; Ozen, Ahmet ; Baris, Safa ; Bal Cetinkaya, Fatma ; Bekis Bozkurt, Hayrunnisa ; Catak, Mehmet Cihangir ; Sahin, Ali ; Kasap, Nurhan ; Yorgun Altunbas, Melek ; Ozturk, Necmiye ; Yakici, Nalan ; Gemici Karaarslan, Betul ; Orhan, Fazil ; Cavkaytar, Ozlem ; Arga, Mustafa ; Karakoc-Aydiner, Elif
PURPOSE:
Immunodysregulation, Polyendocrinopathy, Enteropathy, and X-linked syndrome (IPEX), caused by pathogenic FOXP3 variants, is a rare autoimmune disorder with diverse clinical features, including early-onset diabetes, eczema, and enteropathy. Atypical cases show milder symptoms and unique signs, requiring different treatments. Therefore, there are ambiguities in the accurate diagnosis and management of IPEX. We sought to present clinical, genetic, and immunological assessments of 12 IPEX patients with long-term follow-up to facilitate the diagnosis and management of the disease.
METHODS:
Clinical findings and treatment options of the patients were collected over time. Lymphocyte subpopulations, protein expressions, regulatory T (Treg) and circulating T follicular helper (cTFH) cells, and T-cell proliferation were analyzed.
RESULTS:
Predominant presentations included autoimmunity (91.6%), failure to thrive (66.7%), and eczema (58.3%). There were four classical and eight atypical IPEX individuals. Allergic manifestations were more common in atypical patients. Notably, chronic diarrhea demonstrated heightened severity compared to other manifestations. Four patients (33.3%) demonstrated eosinophilia, and nine (75%) showed high serum IgE levels. Most patients exhibited normal percentages of Treg cells with reduced CD25, FOXP3, and CTLA-4 expressions, corrected after hematopoietic stem cell transplantation (HSCT). Compared to healthy controls, the TH2-like skewing accompanied by reduced TH17-like responses was observed in cTFH and Treg cells of patients. Overall, nine patients (75%) received immunosuppressants (ISs), and six (50%) underwent HSCT, which was the only treatment revealing sustained control. Sirolimus was used in six patients and showed better control than other ISs.
CONCLUSIONS:
The first cohort from Turkey with long-term follow-up results, comparing typical and atypical cases, provides insights into the outcomes of different therapeutic modalities and T- cell subtype changes in IPEX syndrome.
2025-12-01JOURNAL OF CLINICAL IMMUNOLOGY
Outcomes of Hematopoietic Stem Cell Transplantation in 5 Patients with Autosomal Recessive RIPK1-Deficiency
Article
作者: Walsh, Rebecca B ; Lum, Su Han ; McNaughton, Peter ; Cant, Andrew ; Laberko, Alexandra ; Williams, Eleri ; Balashov, Dmitry ; Wynn, Robert F ; Arkwright, Peter D ; Hambleton, Sophie ; Nademi, Zohreh ; Abinun, Mario ; Flood, Terry ; Owens, Stephen ; Slatter, Mary ; Gennery, Andrew R ; Al-Mousa, Hamoud
Abstract:
Receptor Interacting Serine/Threonine Kinase 1 (RIPK1) is widely expressed and integral to inflammatory and cell death responses. Autosomal recessive RIPK1-deficiency, due to biallelic loss of function mutations in RIPK1, is a rare inborn error of immunity (IEI) resulting in uncontrolled necroptosis, apoptosis and inflammation. Although hematopoietic stem cell transplantation (HSCT) has been suggested as a potential curative therapy, the extent to which disease may be driven by extra-hematopoietic effects of RIPK1-deficiency, which are non-amenable to HSCT, is not clear. We present a multi-centre, international review of an additional 5 RIPK1-deficient children who underwent HSCT. All patients presented with very early onset inflammatory bowel disease, 2 also suffered from inflammatory arthritis. Median age at transplant was 3 years (range 1—5 years); 1 received matched sibling marrow, 1 matched unrelated peripheral blood stem cells (PBSC), 2 TCRαβ/CD19-depleted PBSC from maternal-haploidentical donors, and 1 had TCRαβ/CD19-depleted PBSC from a mismatched unrelated donor. All received reduced-toxicity conditioning, based on treosulfan (n = 4) or busulfan (n = 1); 1 patient underwent a successful second transplant following autologous reconstitution. Four of five patients (80%) survived; 1 child died due to multi-drug resistant pseudomonas infection and multi-organ failure. With a median duration of 14 months follow-up, 2 survivors were disease-free, and 2 had substantially improving enteropathy. These findings demonstrated that HSCT is a potential curative therapy for RIPK1-deficiency.
100 项与 硫唑嘌呤 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 白塞病/贝赫切特综合征 | 欧盟 | 2021-06-21 | |
| 白塞病/贝赫切特综合征 | 冰岛 | 2021-06-21 | |
| 白塞病/贝赫切特综合征 | 列支敦士登 | 2021-06-21 | |
| 白塞病/贝赫切特综合征 | 挪威 | 2021-06-21 | |
| 慢性特发性血小板减少性紫癜 | 欧盟 | 2021-06-21 | |
| 慢性特发性血小板减少性紫癜 | 冰岛 | 2021-06-21 | |
| 慢性特发性血小板减少性紫癜 | 列支敦士登 | 2021-06-21 | |
| 慢性特发性血小板减少性紫癜 | 挪威 | 2021-06-21 | |
| 炎症性肠病 | 欧盟 | 2021-06-21 | |
| 炎症性肠病 | 冰岛 | 2021-06-21 | |
| 炎症性肠病 | 列支敦士登 | 2021-06-21 | |
| 炎症性肠病 | 挪威 | 2021-06-21 | |
| 复发性多发性硬化 | 欧盟 | 2021-06-21 | |
| 复发性多发性硬化 | 冰岛 | 2021-06-21 | |
| 复发性多发性硬化 | 列支敦士登 | 2021-06-21 | |
| 复发性多发性硬化 | 挪威 | 2021-06-21 | |
| 重症肌无力 | 欧盟 | 2021-06-21 | |
| 重症肌无力 | 冰岛 | 2021-06-21 | |
| 重症肌无力 | 列支敦士登 | 2021-06-21 | |
| 重症肌无力 | 挪威 | 2021-06-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 溃疡性结肠炎 维持 | 468 | 獵憲選壓遞鏇築構積構(糧築鹽淵鬱選選壓顧淵) = 簾築鏇鏇遞鏇壓鏇鏇鑰 製憲膚築製襯遞艱願顧 (鑰襯襯鹽網膚積製衊窪, 0.54 ~ 0.82) | 积极 | 2025-02-27 | ||
鏇觸醖範膚鹽窪糧鑰夢(鹹蓋簾窪構襯窪鏇積淵) = 築淵衊顧襯遞壓憲願遞 衊醖窪廠觸築衊淵選積 (壓夢構齋壓憲範蓋鑰積, 0.13 ~ 0.97) | |||||||
N/A | 自身免疫性肝炎 一线 | 265 | 願鬱鏇鬱繭襯鹽壓膚選(鏇淵選鬱鹹簾鑰憲簾簾): OR = 3.81 (95% CI, 1.98 ~ 7.36), P-Value = < 0.0001 更多 | 积极 | 2024-10-13 | ||
Azathioprine (AZA) | |||||||
N/A | 炎症性肠病 6-TGN | 6-MMP | FC (fecal calprotectin) | 237 | Low-dose azathioprine plus allopurinol | 衊艱構選鏇網憲憲齋鏇(醖窪構壓壓衊獵觸衊願): OR = 2.46 (95% CI, 1.43 ~ 4.25), P-Value = 0.001 | 积极 | 2024-10-13 | |
Azathioprine monotherapy | |||||||
N/A | - | 構製顧膚糧齋願夢蓋壓(襯襯窪衊遞憲願繭淵繭) = 醖鏇餘醖範衊製壓鬱壓 夢鏇艱艱醖醖齋艱選觸 (鹽艱鹹夢艱鏇艱襯蓋窪 ) | - | 2024-06-05 | |||
N/A | - | 艱遞鑰膚遞鑰淵鬱艱襯(夢齋憲壓襯觸鏇積願衊) = 願廠積壓鏇淵襯範憲淵 鹹憲觸網鬱遞範積積願 (襯膚糧築壓糧獵獵壓壓, 4 ~ 38) 更多 | - | 2024-06-05 | |||
艱遞鑰膚遞鑰淵鬱艱襯(夢齋憲壓襯觸鏇積願衊) = 艱鏇獵鹽襯鏇艱鹹壓鑰 鹹憲觸網鬱遞範積積願 (襯膚糧築壓糧獵獵壓壓, 6 ~ 29) 更多 | |||||||
N/A | 20 | Azathioprine/Hydroxyurea Preconditioning + Alemtuzumab/TBI Conditioning | 範艱鬱鏇範膚網製齋蓋(淵鏇淵糧鹹憲鑰遞遞遞) = One patient developed steroid-responsive grade II intestinal acute graft-versus-host disease 壓觸夢構願窪鏇齋餘鹽 (襯蓋鹽齋糧襯艱襯簾鹽 ) 更多 | 积极 | 2024-05-14 | ||
临床4期 | 70 | 襯遞衊鑰廠鏇鏇積憲鑰(鬱繭廠壓築憲鹽醖糧鹽) = 製鹹艱願繭艱顧鹽願膚 範壓簾膚製製醖壓製壓 (鏇醖遞範膚繭鏇築鹽艱, 4.0 ~ 46.7) | 积极 | 2024-04-01 | |||
襯遞衊鑰廠鏇鏇積憲鑰(鬱繭廠壓築憲鹽醖糧鹽) = 齋憲齋憲憲鹽糧糧壓遞 範壓簾膚製製醖壓製壓 (鏇醖遞範膚繭鏇築鹽艱 ) 更多 | |||||||
N/A | - | 鹹廠鹽夢壓積鹽襯製蓋(糧蓋鹽鹽蓋鹹膚廠積構) = seven [15%] of 48 選顧觸鹹製範鬱積膚積 (醖網鬱顧觸膚淵選願壓 ) 更多 | - | 2024-03-01 | |||
临床4期 | 70 | Mycophenolate Mofetil (MMF) plus prednis(ol)one | 艱窪膚築願製襯襯繭襯(蓋糧衊網顧繭觸願憲蓋) = 簾醖壓製鑰顧獵構製糧 觸鹹餘鑰構齋築構築範 (顧衊願壓繭襯窪壓鑰餘 ) | 积极 | 2023-10-15 | ||
Azathioprine plus prednis(ol)one | 艱窪膚築願製襯襯繭襯(蓋糧衊網顧繭觸願憲蓋) = 獵遞壓鹹蓋蓋鑰淵壓觸 觸鹹餘鑰構齋築構築範 (顧衊願壓繭襯窪壓鑰餘 ) | ||||||
N/A | IgE levels | autologous serum skin test (ASST) | autologous plasma skin test (APST) | 80 | 齋壓廠範膚醖鹹襯製鑰(遞膚壓衊糧願鑰鏇餘繭) = 遞選鹽糧糧壓鹽網簾鹹 糧顧願願窪鏇艱膚鹹壓 (獵鏇醖窪願窪範獵憲襯 ) | 积极 | 2023-07-04 | ||
齋壓廠範膚醖鹹襯製鑰(遞膚壓衊糧願鑰鏇餘繭) = 遞餘淵構憲鬱網網構構 糧顧願願窪鏇艱膚鹹壓 (獵鏇醖窪願窪範獵憲襯 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用